Skip to main content

Drug Interactions between ipilimumab and vemurafenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ipilimumab vemurafenib

Applies to: ipilimumab and vemurafenib

MONITOR: Coadministration of vemurafenib with ipilimumab may potentiate the risk of hepatotoxicity. In a dose-finding clinical trial, grade 3 increases in transaminases with or without concomitant increases in total bilirubin occurred in 6 of 10 patients who received concurrent vemurafenib (960 mg or 720 mg twice a day) and ipilimumab (3 mg/kg).

MANAGEMENT: The safety and effectiveness of vemurafenib in combination with ipilimumab have not been established. Liver transaminases, alkaline phosphatase, and bilirubin should be monitored prior to initiation of vemurafenib treatment and monthly during treatment, or as clinically indicated. Laboratory abnormalities should be managed with dosage reduction, treatment interruption, or treatment discontinuation in accordance with the product labeling.

References (2)
  1. (2011) "Product Information. Yervoy (ipilimumab)." Bristol-Myers Squibb
  2. (2011) "Product Information. Zelboraf (vemurafenib)." Genentech

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer